Onconetix Dividend Paid And Capex Coverage Ratio from 2010 to 2024
| ONCO Stock | USD 0.63 0.17 21.25% |
Dividend Paid And Capex Coverage Ratio | First Reported 2010-12-31 | Previous Quarter (246.73) | Current Value (259.07) | Quarterly Volatility 285.87667627 |
Check Onconetix financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Onconetix's main balance sheet or income statement drivers, such as Interest Income of 0.0, Depreciation And Amortization of 46.1 K or Other Operating Expenses of 37.9 M, as well as many indicators such as Price To Sales Ratio of 1.9 K, Dividend Yield of 0.0 or PTB Ratio of 2.2. Onconetix financial statements analysis is a perfect complement when working with Onconetix Valuation or Volatility modules.
Onconetix | Dividend Paid And Capex Coverage Ratio |
Latest Onconetix's Dividend Paid And Capex Coverage Ratio Growth Pattern
Below is the plot of the Dividend Paid And Capex Coverage Ratio of Onconetix over the last few years. It is Onconetix's Dividend Paid And Capex Coverage Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Onconetix's overall financial position and show how it may be relating to other accounts over time.
| Dividend Paid And Capex Coverage Ratio | 10 Years Trend |
|
Dividend Paid And Capex Coverage Ratio |
| Timeline |
Onconetix Dividend Paid And Capex Coverage Ratio Regression Statistics
| Arithmetic Mean | (298.67) | |
| Coefficient Of Variation | (95.72) | |
| Mean Deviation | 186.21 | |
| Median | (183.36) | |
| Standard Deviation | 285.88 | |
| Sample Variance | 81,725 | |
| Range | 916 | |
| R-Value | (0.45) | |
| Mean Square Error | 70,177 | |
| R-Squared | 0.20 | |
| Significance | 0.09 | |
| Slope | (28.78) | |
| Total Sum of Squares | 1.1M |
Onconetix Dividend Paid And Capex Coverage Ratio History
About Onconetix Financial Statements
Onconetix investors utilize fundamental indicators, such as Dividend Paid And Capex Coverage Ratio, to predict how Onconetix Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Dividend Paid And Capex Coverage Ratio | (246.73) | (259.07) |
Pair Trading with Onconetix
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Onconetix position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Onconetix will appreciate offsetting losses from the drop in the long position's value.Moving together with Onconetix Stock
| 0.63 | A | Agilent Technologies Sell-off Trend | PairCorr |
| 0.72 | ME | 23Andme Holding | PairCorr |
| 0.75 | VALN | Valneva SE ADR | PairCorr |
| 0.82 | JNJ | Johnson Johnson Sell-off Trend | PairCorr |
Moving against Onconetix Stock
| 0.75 | MDGL | Madrigal Pharmaceuticals | PairCorr |
| 0.63 | RNXT | RenovoRx | PairCorr |
| 0.39 | KEP | Korea Electric Power | PairCorr |
| 0.38 | NXGLW | NexGel Warrant | PairCorr |
The ability to find closely correlated positions to Onconetix could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Onconetix when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Onconetix - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Onconetix to buy it.
The correlation of Onconetix is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Onconetix moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Onconetix moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Onconetix can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Onconetix Correlation against competitors. To learn how to invest in Onconetix Stock, please use our How to Invest in Onconetix guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Onconetix. If investors know Onconetix will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Onconetix listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (109.20) | Revenue Per Share 2.892 | Return On Assets (0.22) | Return On Equity (17.58) |
The market value of Onconetix is measured differently than its book value, which is the value of Onconetix that is recorded on the company's balance sheet. Investors also form their own opinion of Onconetix's value that differs from its market value or its book value, called intrinsic value, which is Onconetix's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Onconetix's market value can be influenced by many factors that don't directly affect Onconetix's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Onconetix's value and its price as these two are different measures arrived at by different means. Investors typically determine if Onconetix is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Onconetix's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.